VirtualScopics to Present at Rodman & Renshaw Annual Global Investment Conference
ROCHESTER, N.Y., Sept. 1, 2011 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today it has been invited to present at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held at the Waldorf Astoria Hotel in New York City on September 11-13, 2011.
The presentation by VirtualScopics' Chief Business & Financial Officer Molly Henderson is scheduled to begin at 12:05pm, ET, on Tuesday, September 13th. For more information about the conference or to schedule a one-on-one meeting with VirtualScopics' management, contact your Rodman & Renshaw representative or the conference desk at 212-920-3595.
To access the live or archived webcast of the event, visit the "Investor Relations" section of VirtualScopics' website, www.virtualscopics.com.
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.
The Shoreham Group
Chief Business and Financial Officer, Sr. Vice President
80 Eighth Ave, Ste 1107
500 Linden Oaks
New York, NY 10011
Rochester, New York 14625
+1 212 242 7777 Direct
+1 585 249.6231
SOURCE VirtualScopics, Inc.
More by this Source
VirtualScopics Reports First Quarter 2013 Results
May 15, 2013, 08:00 ET
VirtualScopics Schedules First Quarter 2013 Earnings Announcement
Apr 30, 2013, 15:53 ET
VirtualScopics Receives Additional Time to Regain Compliance with Nasdaq
Feb 28, 2013, 16:13 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.